Polypharmacy and bipolar disorder: What's personality got to do with it?

International Journal of Neuropsychopharmacology

Volumn 17, Issue 7, 2014, Pages 1053-1061

  Sachs, G S ^a,b   Peters, A T ^a   Sylvia, L ^a,b   Grunze, H ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bipolar disorder; medication; personality; polypharmacy

Indexed keywords

ARIPIPRAZOLE; DOPAMINE; LITHIUM; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG USE; EXTRAVERSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PERSONALITY; PERSONALITY TEST; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; SELF REPORT; SYMPTOM ASSESSMENT; YOUNG MANIA RATING SCALE; INTERVIEW; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ADULT; BIPOLAR DISORDER; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; PERSONALITY; PERSONALITY INVENTORY; POLYPHARMACY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS;

EID: 84901429635     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000953     Document Type: Review

References (40)

1. Baldassano CF (2006). Illness course, comorbidity, gender, and suicidality in patients with bipolar disorder. J Clin Psychiatry 67(Suppl. 11):8-11.
2. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L (2008). Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatric Serv 59:1175-1183.
3. Barnett JH, Huang J, Perlis RH, Young MM, Rosenbaum JF, Nierenberg AA, Sacha G, Nimgaonkar VL, Miklowitz DJ, Smoller JW (2011). Personality and bipolar disorder: dissecting state and trait associations between mood and personality. Psychol Med 41:1593-1604.
4. Bishop S, Gaughran F, Scott J (2008). The prevalence and needs of individuals with bipolar disorders using mental health services in Lewisham. Internal Report, South London and Maudsley National Health Service Foundation Trust.
5. Conforti D, Borgherini G, Fiorellini Bernardis LA, Magni G (1999). Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination. Int Clin Psychopharm 14:197-198.
6. Costa PT Jr, Fagan PJ, Piedmont RL, Ponticas Y, Wise TN (1992). The five-factor model of personality and sexual functioning in outpatient men and women. Psychiatric Med 10:199-215.
7. Freeman MP, Stoll AL (1998). Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 155:12-21.
8. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM (2000). The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61:9-15.
9. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E and 169 collaborators (2010). Lithium plus valproate combination therapy vs monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375:385-395.
10. Goldberg JF, Brooks JO III, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, Miklowitz DJ, Ketter TA, Sachs GS, Thase ME (2009). Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 70:155-162.
11. Goodwin GM (2009). Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 23(4):346-388.
12. Goren JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, Chan J, Hermann RC (2008). When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Joint Comm J Quality Patient Safety 34:571-582.
13. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, Kasper S, WFSBP Task Force (2009). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World Journal of Biological Psychiatry, 10(2):85-116.
14. Lin D, Mok H, Yatham LN (2006). Polytherapy in bipolar disorder. Central Nervous System Drugs 20:29-42.
15. Magalhaes PV, Kapczinski F, Nierenberg AA, Deckersbach T, Weisinger D, Dodd S, Berk M (2012). Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatrica Scand 125(4):303-308.
16. Mojtabai R, Olfson M (2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67:26-36.
17. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
18. Post DE (2007). Quetiapine in the successful combination treatment of an assaultive patient with treatment-resistant schizoaffective disorder. Behav Med 33:11-14.
19. Post RM, Ketter TA, Pazzaglia PJ, Denicoff K, George MS, Callahan A, Leverich G, Frye M (1996). Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl 11:153-180.
20. Preskorn SH (2006). Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. J Psychopharm 20(4 Suppl.):85-94.
21. Preskorn SH, Lacey RL (2007). Polypharmacy: when is it rational? J Psychiatric Practice 13:97-105.
22. Reilly-Harrington NA, Debonis D, Leon AC, Sylvia L, Perlis R, Lewis D, Sachs GS (2010). The interactive computer interview for mania. Bipolar Dis 12:521-527.
23. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, Sweitzer DE (2004). Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Dis 6:213-223.
24. Sachs GS, Dupuy JM, Wittmann CW (2011a). The pharmacologic treatment of bipolar disorder. J Clin Psychiatry 72:704-715.
25. Sachs GS, Gardner-Schuster EE (2007). Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatrica Scand Suppl, 27-34.
26. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL (2002). Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 159:1146-1154.
27. Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B (2011b). Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 72:1413-1422.
28. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher ML, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England J Med 356:1711-1722.
29. Thompson A, Sullivan SA, Barley M, Strange SO, et al. (2008). The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards-a cluster randomized controlled trial. Psych Med 38:705-715.
30. Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Cal;abrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A (2002). Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 59:62-69.
31. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079-1088.
32. van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MJ, Vieta E, Nolan WA, LamLit Study Group (2009). Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 70:223-231.
33. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M (2008a). Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affective Dis 109:251-263.
34. Vieta E, T'Joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R, Owen R, Nameche L (2008b). Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 165:1316-1325.
35. Vieta E, Murru A, Pueyo MJ (2010) Guia sobre el maneig del trastorn bipolar a Catalunya (Guidelines on the management of bipolar disorder in Catalunya). Available at: http://www.gencat.cat/salut/depsan/units/aatrm/pdf/ guia-trastorn-bipolar-aiaqs-2010ca.pdf
36. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A (2003). Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 182:141-147.
37. Yatham LN, Vieta E, Young AH, Moller HJ, Paulson B, Vågerö M (2007). A double blind, randomized, placebocontrolled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharm 22:212-220.
38. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 11(3):225-255.
39. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429-435.
40. Zarate CA Jr, Quiroz JA (2003). Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Dis 5:217-225.